Open AccessCB1 and CB2 Cannabinoid Receptor Agonists Induce Peripheral Antinociception by Activation of the Endogenous Noradrenergic System
Author(s) -
Thiago Roberto Lima Romero,
Lívia C. Resende,
Luciana Souza Guzzo,
Igor Dimitri Gama Duarte
Publication year - 2013
Publication title -
anesthesia and analgesia/anesthesia and analgesia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.404
H-Index - 201
eISSN - 1526-7598
pISSN - 0003-2999
DOI - 10.1213/ane.0b013e3182707859
Subject(s) - am251 , anandamide , cannabinoid , cannabinoid receptor , pharmacology , yohimbine , cannabinoid receptor type 2 , antagonist , prazosin , medicine , endocannabinoid system , rauwolscine , receptor antagonist , chemistry , receptor
Cannabinoid agonists induce norepinephrine release in central, spinal, and peripheral sites. Previous studies suggest an interaction between the cannabinoid and adrenergic systems on antinociception. In this study, we sought to verify whether the CB1 and CB2 cannabinoid receptor agonists anandamide and N-palmitoyl-ethanolamine (PEA), respectively, are able to induce peripheral antinociception via an adrenergic mechanism.